Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Beam Therapeutics stock | $90.71

Learn how to easily invest in Beam Therapeutics stock.

Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Beam Therapeutics employs 266 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Beam Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BEAM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Beam Therapeutics stock price (NASDAQ: BEAM)

Use our graph to track the performance of BEAM stocks over time.

Beam Therapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$90.71
52-week range$29.43 - $138.52
50-day moving average $96.97
200-day moving average $89.84
Wall St. target price$128.57
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.12

Buy Beam Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Beam Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Beam Therapeutics price performance over time

Historical closes compared with the close of $90.71 from 2021-10-18

1 week (2021-10-12) 3.24%
1 month (2021-09-17) -11.86%
3 months (2021-07-19) 0.48%
6 months (2021-04-19) 27.96%
1 year (2020-10-19) 184.54%
2 years (2019-10-15) N/A
3 years (2018-10-15) N/A
5 years (2016-10-15) N/A

Beam Therapeutics financials

Revenue TTM $24,000
Gross profit TTM $-91,956,000
Return on assets TTM -35.36%
Return on equity TTM -104.63%
Profit margin 0%
Book value $8.69
Market capitalisation $6.2 billion

TTM: trailing 12 months

Shorting Beam Therapeutics shares

There are currently 5.0 million Beam Therapeutics shares held short by investors – that's known as Beam Therapeutics's "short interest". This figure is 3.5% down from 5.2 million last month.

There are a few different ways that this level of interest in shorting Beam Therapeutics shares can be evaluated.

Beam Therapeutics's "short interest ratio" (SIR)

Beam Therapeutics's "short interest ratio" (SIR) is the quantity of Beam Therapeutics shares currently shorted divided by the average quantity of Beam Therapeutics shares traded daily (recently around 743392.33038348). Beam Therapeutics's SIR currently stands at 6.78. In other words for every 100,000 Beam Therapeutics shares traded daily on the market, roughly 6780 shares are currently held short.

However Beam Therapeutics's short interest can also be evaluated against the total number of Beam Therapeutics shares, or, against the total number of tradable Beam Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Beam Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Beam Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1146% of the tradable shares (for every 100,000 tradable Beam Therapeutics shares, roughly 115 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Beam Therapeutics.

Find out more about how you can short Beam Therapeutics stock.

Beam Therapeutics share dividends

We're not expecting Beam Therapeutics to pay a dividend over the next 12 months.

Beam Therapeutics overview

Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc. ; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Beam Therapeutics is owned by insiders or institutions?
Currently 2.034% of Beam Therapeutics shares are held by insiders and 79.621% by institutions.
How many people work for Beam Therapeutics?
Latest data suggests 266 work at Beam Therapeutics.
When does the fiscal year end for Beam Therapeutics?
Beam Therapeutics's fiscal year ends in December.
Where is Beam Therapeutics based?
Beam Therapeutics's address is: 26 Landsdowne Street, Cambridge, MA, United States, 02139
What is Beam Therapeutics's ISIN number?
Beam Therapeutics's international securities identification number is: US07373V1052
What is Beam Therapeutics's CUSIP number?
Beam Therapeutics's Committee on Uniform Securities Identification Procedures number is: 073730103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site